European shares led higher by tech, banks as US slowdown fears ease
For a Reuters live blog on U.S., UK and European stock markets, click LIVE/ or type LIVE/ in a news window
Adyen tops profit forecast, shares jump
Admiral surges on forecast-beating profit, special dividend
Orsted books new impairment losses, shares drop
Geberit falls after forecasting flat 2024 sales
STOXX 600 up 1.2%
Updated at 1600 GMT
By Ankika Biswas and Pranav Kashyap
Aug 15 (Reuters) -Technology and bank shares led Europe's benchmark stock index more than 1% higher on Thursday, with risk appetite boosted by strong U.S. retail sales data that eased fears of a slowdown in the world's largest economy.
The pan-European STOXX 600 .STOXX closed at a two-week high, up 1.2% on the day to complete a reversal of the losses posted during the global market turmoil in the first half of August.
All the major regional bourses, including those of Germany .GDAXI, France .FCHI, Italy .FTMIB and Spain .IBEX were also more than 1% higher.
U.S. retail sales rose more than expected in July, keeping investor bets on a smaller than 50-basis-point Federal Reserve interest rate cut intact.
"The numbers should lay to rest - at least for the moment - all of the doom and gloom that was expressed at the beginning of this month," said Chris Zaccarelli, chief investment officer for Independent Advisor Alliance.
"The Fed can begin a rate-cutting cycle without the economy entering recession, and history shows this is an extremely positive environment for the stock market."
Rate-sensitive technology shares .SX8P, among the hardest hit during the rout, were Thursday's biggest gainers, up 2.6% with semiconductor players such as ASML Holding ASML.AS and ASM International ASMI.AS leading the way.
The volatility "fear gauge" .V2TX retreated to its lowest level since late July.
Banks .SX7E, retail .SXRP and automobiles .SXAP were also among the top performers, although most sectors gained on the day.
Dutch payments company Adyen ADYEN.AS was the strongest individual performer, jumping 12% to top the STOXX 600 after market share gains helped it beat half-year core profit expectations.
British motor and home insurer Admiral ADML.L climbed 6.5% after posting a forecast-beating first-half profit.
AstraZeneca AZN.L rose nearly 2%, marking a record high for a fourth-straight session, after the U.S. Food and Drug Administration granted its blockbuster cancer drug Imfinzi a priority review for patients with limited-stage small cell lung cancer in the United States.
Renewable energy group Orsted ORSTED.CO was the day's worst Stoxx 600 performer, slumping 7.2% after booking 3.9 billion Danish crowns ($574.4 million) in impairment losses in second quarter.
Swedish games developer Embracer EMBRACb.ST fell more than 7% after a reporting a 50% drop in first-quarter operating profit, and Swiss plumbing materials supplier Geberit GEBN.S lost nearly 2% after disappointing with a forecast for 2024 organic sales similar to those of last year.
($1 = 6.7899 Danish crowns)
Reporting by Pranav Kashyap and Ankika Biswas in Bengaluru; Editing by Subhranshu Sahu and Janane Venkatraman
Related Assets
Latest News
Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.
All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.
Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.
